ethyl 3-[[2-[(4-cyanoanilino)methyl]-3H-benzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: ethyl 3-[[2-[(4-cyanoanilino)methyl]-3H-benzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
• 化学式: C₂₆H₂₄N₆O₃
• 分子量: 468.5
• InChiKey: TZKBZSKYKDNRNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] IMPROVED PROCESSES FOR THE PREPARATION OF DABIGATRAN ETEXILATE USING NOVEL INTERMEDIATES<br/>[FR] PROCÉDÉS AMÉLIORÉS POUR LA PRÉPARATION DE DABIGATRAN ÉTEXILATE AU MOYEN DE NOUVEAUX INTERMÉDIAIRES
  申请人：SYMED LABS LTD

  公开号：WO2015132794A1

  公开（公告）日：2015-09-11

  Disclosed herein are novel, commercially viable and industrially advantageous processes for the preparation of Dabigatran or a salt thereof, in high yield and purity, using novel intermediate compounds. The novel process solves the drawbacks associated with the prior processes and is commercially viable for preparing Dabigatran and its salts or derivatives thereof.

  本文揭示了一种新颖的、商业上可行的和工业上有利的过程，用于制备Dabigatran或其盐，收率高，纯度高，使用新颖的中间化合物。这种新的过程解决了先前过程所涉及的缺点，并且在制备Dabigatran及其盐或衍生物方面具有商业上的可行性。
• DABIGATRAN ETEXILATE AND RELATED SUBSTANCES, PROCESSES AND COMPOSITIONS, AND USE OF THE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS
  申请人：Serra Miralles Judit

  公开号：US20140076036A1

  公开（公告）日：2014-03-20

  The present invention relates to dabigatran etexilate and related substances and use of the substances as reference standards and markers. There are also provided processes of detecting the substances in samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof, and also for analyzing the purity of samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof. There are still further provided processes of preparing dabigatran etexilate and related substances, and pharmaceutical compositions containing the same.

  本发明涉及达比加群酯和相关物质，以及将这些物质用作参考标准和标记的用途。还提供了检测达比加群酯或其药学上可接受的盐或溶剂的样品中这些物质的过程，以及分析达比加群酯或其药学上可接受的盐或溶剂的样品纯度的过程。还提供了制备达比加群酯和相关物质以及含有它们的制药组合物的过程。
• US9086390B2
  申请人：——

  公开号：US9086390B2

  公开（公告）日：2015-07-21
• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION D'ÉTEXILATE-MÉSYLATE DE DABIGATRAN
  申请人：ALEMBIC PHARMACEUTICALS LTD

  公开号：WO2014020555A2

  公开（公告）日：2014-02-06

  The present invention relates to an improved process for the preparation of 1-methyl-2- [N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl- carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide methanesulfonate salt (Dabigatran etexilate mesylate ). Further, the present invention provides a process for purification of Dabigatran etexilate mesylate. Further, the present invention provides provide a process for the preparation of 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N- (2-ethoxy carbonyl ethyl)-amide of formula (VI) an intermediate of Dabigatran.